You are here

MegaTrans - human transporter machine learning models

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41GM131433-01A1
Agency Tracking Number: R41GM131433
Amount: $210,712.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 400
Solicitation Number: PA18-575
Timeline
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-04-01
Award End Date (Contract End Date): 2021-03-31
Small Business Information
5616 HILLTOP NEEDMORE RD
Fuquay Varina, NC 27526-9278
United States
DUNS: 079704473
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 SEAN EKINS
 (215) 687-1320
 sean@collaborationspharma.com
Business Contact
 SEAN EKINS
Phone: (215) 687-1320
Email: collaborationspharma@gmail.com
Research Institution
 UNIVERSITY OF ARIZONA
 
PO BOX 210158, ROOM 510
TUCSON, AZ 85721-0158
United States

 Nonprofit college or university
Abstract

Summary Being able to predict interactions with important human transporters would be of value to new drug design to avoid compounds that interact with them and cause undesirable side effectsOATP BSLCO Band OATP BSLCO Bare `uptakeandapostransporters largely restricted to the sinusoidal aspect of hepatocytesThey both transport a wide variety of structurally unrelated compoundsincluding members of several clinically important drug families such as statinssartans and angiotensin converting enzymeACEinhibitorsWe now propose to test overdrugs againstsubstrates for each transporter in vitroWe will then use these data to curate and validate machine learning modelsWe will also use an array of machine learning methods as well as multiple model evaluation metricsThis will enable us to develop a web based software tool called MegaTrans that will encourage the user to input their own compound structures and generate predictions for interactions with transporter s of interest and then visualize the similarity to the training set of each model using several different visualization methodsThe return on investment of such a tool would be that it could assist in the design and selection of more favorable compounds that avoid transporters of interest while also saving time and moneyIt could also identify compounds that are already approved that might present a drug interaction riskPredicting such behavior seen in vivo is ideal and will lead to the prioritization of compounds to test in vitro for potential drug drug interactionsIn Phase II we would greatly expand the number of transporters which we would generate data on and build models such that we could address all the major transporters of interest to drug discovery Narrative The objective ofMegaTransis to develop a new computational system and tools for integrating human transporter data into drug discovery pipelinesas well as enabling its analysis and visualizationThis will then enable improved computational tool development for in vitro to in vivo extrapolation of xenobiotic exposures across a range of assay typesIt will also assist with developing computational tools for quantitatively modeling drug drug interactions of xenobioticsAcross Phase I and Phase II we will generate data for transporters which currently have a paucity of data in the public domainuse validated machine learning algorithmsaccess the latest curated datasets and develop a user intuitive interface and visualization system to enable predictions

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government